- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07069738
- Original rettssak
Sikkerhet og effektivitet av venstrebundets grenområde stimulerende kontra konvensjonell hjertesynkroniseringsterapi i hjertesvikt (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jacqueline Beaulieu
- Telefonnummer: 1-800-227-3422
- E-post: jacqueline.beaulieu@bsci.com
Studiesteder
-
-
Alabama
-
Huntsville, Alabama, Forente stater, 35801
- Rekruttering
- Heart Center Research, LLC
-
Ta kontakt med:
- John Jennings, Dr.
-
Hovedetterforsker:
- John Jennings, Dr.
-
Mobile, Alabama, Forente stater, 36608
- Rekruttering
- Mobile Infirmary Medical Center
-
Ta kontakt med:
- Ernest Matthew Quin, Dr.
-
Hovedetterforsker:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Rekruttering
- Mayo Clinic Phoenix
-
Ta kontakt med:
- Mayank Sardana, MD
-
Hovedetterforsker:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, Forente stater, 72401
- Rekruttering
- Arrhythmia Research Group
-
Ta kontakt med:
- Devi Nair, Dr.
-
Hovedetterforsker:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, Forente stater, 92037
- Rekruttering
- Scripps Memorial Hospital
-
Ta kontakt med:
- Nicolas Olson, MD
-
Hovedetterforsker:
- Nicolas Olson, MD
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Cedars Sinai Medical Center
-
Hovedetterforsker:
- Ashkan Ehdaie, MD
-
Ta kontakt med:
- Ashkan Ehdaie, MD
-
Oakland, California, Forente stater, 94609
- Rekruttering
- Alta Bates Summit Medical Center
-
Ta kontakt med:
- Rajan Shah, Dr.
-
Hovedetterforsker:
- Rajan Shah, Dr.
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- Pacific Heart Institute
-
Ta kontakt med:
- Stephen Tang, MD
-
Hovedetterforsker:
- Stephan Tang, MD
-
Torrance, California, Forente stater, 90505
- Rekruttering
- Torrance Medical Center
-
Hovedetterforsker:
- Gene Kim, MD
-
Ta kontakt med:
- Gene Kim, MD
-
Ventura, California, Forente stater, 93003
- Rekruttering
- Cardiology Associates Medical Group, Inc.
-
Ta kontakt med:
- Jonathan Dukes, Dr.
-
Hovedetterforsker:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Washington Hospital Center
-
Ta kontakt med:
- Cyrus Hadadi, MD
-
Hovedetterforsker:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, Forente stater, 34239
- Rekruttering
- Sarasota Memorial Hospital
-
Ta kontakt med:
- Antonio Moretta, Dr.
-
Hovedetterforsker:
- Antonio Moretta, Dr.
-
Tampa, Florida, Forente stater, 33613
- Rekruttering
- AdventHealth Tampa
-
Hovedetterforsker:
- Kenneth Yamamura, MD
-
Ta kontakt med:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30309
- Rekruttering
- Piedmont Hospital
-
Ta kontakt med:
- Kavita Krishnasamy, MD
-
Hovedetterforsker:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital
-
Ta kontakt med:
- Anand Shah, MD
-
Hovedetterforsker:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, Forente stater, 83642
- Rekruttering
- St. Luke's Idaho Cardiology Associates
-
Ta kontakt med:
- Justice Oranefo, MD
-
Hovedetterforsker:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, Forente stater, 60521
- Rekruttering
- University of Chicago
-
Ta kontakt med:
- Shrinath Yeshwant, MD
-
Hovedetterforsker:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, Forente stater, 60540
- Tilbaketrukket
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46250
- Rekruttering
- Community Heart and Vascular Hospital
-
Ta kontakt med:
- Krishna Malineni, MD
-
Hovedetterforsker:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa Hospitals and Clinics
-
Hovedetterforsker:
- Paari Dominic, MD
-
Ta kontakt med:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40207
- Rekruttering
- Baptist Hospital East Louisville
-
Hovedetterforsker:
- Kevin Parrott, MD
-
Ta kontakt med:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, Forente stater, 02720
- Rekruttering
- Southcoast Physicians Group
-
Ta kontakt med:
- Arnoldas Giedrimas, MD
-
Hovedetterforsker:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan Hospitals
-
Hovedetterforsker:
- Thomas Crawford, MD
-
Ta kontakt med:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, Forente stater, 49525
- Rekruttering
- Corewell Health
-
Ta kontakt med:
- Jawad Wassim, MD
-
Hovedetterforsker:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, Forente stater, 55805
- Tilbaketrukket
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, Forente stater, 56303
- Tilbaketrukket
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07932
- Rekruttering
- Morristown Medical Center
-
Ta kontakt med:
- Michael Katz, MD
-
Hovedetterforsker:
- Michael Katz, MD
-
-
New York
-
Albany, New York, Forente stater, 12211
- Rekruttering
- Capital Cardiology Associates
-
Ta kontakt med:
- Rizwan Alimohammad, MD
-
Hovedetterforsker:
- Rizwan Alimohammad, MD
-
Flushing, New York, Forente stater, 11355
- Rekruttering
- New York Hospital Queens
-
Ta kontakt med:
- Seth Goldbarg, Dr.
-
Hovedetterforsker:
- Seth Goldbarg, Dr.
-
New York, New York, Forente stater, 10021
- Rekruttering
- Weill Cornell Medical University
-
Ta kontakt med:
- Jim Cheung, Dr.
-
Hovedetterforsker:
- Jim Cheung, Dr.
-
New York, New York, Forente stater, 14621
- Rekruttering
- Rochester General Hospital
-
Ta kontakt med:
- Dmitry Chuprun, MD
-
Hovedetterforsker:
- Dmitry Chuprun, MD
-
Syracuse, New York, Forente stater, 13057
- Rekruttering
- SUNY-Upstate Medical University
-
Ta kontakt med:
- Jorge Romero, MD
-
Hovedetterforsker:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Rekruttering
- Sanger Heart and Vascular Institute
-
Ta kontakt med:
- Navid Nafissi, MD
-
Hovedetterforsker:
- Navid Nafissi, MD
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Medical Center
-
Ta kontakt med:
- Daniel Friedman, MD
-
Hovedetterforsker:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43219
- Rekruttering
- Mount Carmel Health System
-
Ta kontakt med:
- Kamel Addo, MD
-
Hovedetterforsker:
- Kamel Addo, MD
-
Columbus, Ohio, Forente stater, 43214
- Rekruttering
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Ta kontakt med:
- Anish Amin, MD
-
Hovedetterforsker:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Penn Presbyterian Medical Center
-
Ta kontakt med:
- John Bullinga, MD
-
Hovedetterforsker:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, Forente stater, 18702
- Rekruttering
- Geisinger Wyoming Valley
-
Hovedetterforsker:
- Pugazhendhi Vijayaraman, MD
-
Ta kontakt med:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57108
- Rekruttering
- Avera Heart Hospital of South Dakota
-
Ta kontakt med:
- Christopher Stanton, Dr.
-
Hovedetterforsker:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37205
- Rekruttering
- St.Thomas Health
-
Ta kontakt med:
- Ricardo Lugo, MD
-
Hovedetterforsker:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, Forente stater, 75093
- Rekruttering
- Heart Hospital Baylor Plano
-
Ta kontakt med:
- Mustafa Dohadwala, MD
-
Hovedetterforsker:
- Mustafa Dohadwala, MD
-
Tyler, Texas, Forente stater, 75701
- Rekruttering
- Christus Trinity Mother Frances Health System
-
Ta kontakt med:
- Stanislov Weiner, Dr.
-
Hovedetterforsker:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- Rekruttering
- University of Virginia Medical Center
-
Hovedetterforsker:
- Pamela Mason, MD
-
Ta kontakt med:
- Pamela Mason, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Eksperimentell: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Tidsramme: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Win ratio composite assessment
Tidsramme: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Tidsramme: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Tidsramme: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C2403
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .